Express delivery and free returns within 21 days

Monday, June 27, 2022

MEDICAL DEVICE NEWS MAGAZINE

|

Contact us 561.316.3330

GlucoTrack, Inc. Announces Effectiveness of Corporate Name Change and Ticker Symbol Change

To begin trading under the Nasdaq Symbol GCTK

GlucoTrack, Inc. (Nasdaq: GCTK) (“GlucoTrack” or the “Company”), formerly known as Integrity Applications, Inc., (Nasdaq: IGAP), innovator of GlucoTrack®, a non-invasive device and digital health platform for measuring glucose levels in people with Type 2 diabetes and prediabetes, announced today that it has completed its corporate name and ticker symbol change on the Nasdaq Capital Market, to be effective at the commencement of trading today, March 14, 2022.

The corporate name change and ticker symbol change do not affect the rights of the Company’s stockholders nor the number of outstanding shares of the Company’s common stock.

Registered stockholders holding their shares of common stock in book-entry or through a bank, broker or other nominee form do not need to take any action in connection with these changes.

For those stockholders holding physical stock certificates, the Company’s transfer agent, American Stock Transfer & Trust Company, will send instructions for exchanging those certificates for new certificates representing the new name and ticker symbol. Any shareholders with questions may reach American Stock Transfer & Trust Company at (877) 248-6417.

GlucoTrack, Inc. (NASDAQ: GCTK), (formerly known as Integrity Applications, Inc.) is focused on the design, development, and commercialization of non-invasive glucose monitoring technologies for people with type 2 diabetes and prediabetes. The Company has developed GlucoTrack®, a proprietary non-invasive glucose monitoring device designed to obtain glucose level measurements without the pain, incremental cost, difficulty, or discomfort of conventional invasive finger stick devices. GlucoTrack, Inc. is a Delaware corporation, with headquarters in the United States and an R&D site in Or Yehuda, Israel. For more information, please visit http://www.integrity-app.com/ and http://www.glucotrack.com.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.
Subscribe to Medical Device News Magazine

CAPS Medical Enrolls Patients from Sheba Medical Center in First Ever Study for Treatment of Bladder Cancer Using Selective Endoscopic Cancer Treatment Technology

CAPS Medical is conducting revolutionary endoscopic treatment of tumors using non-thermal plasma, suitable for a variety of cancer types.

Envoy Medical Reports FDA Approves Clinical Trial of First Fully Implanted Cochlear Implant

If approved by the FDA, the Acclaim would be the first-of-its-kind cochlear implant designed to be fully implanted and use the ear, rather than a microphone, to pick up sound notes Envoy Medical.

Radicle Science Reports History’s Largest Cannabinoid Trial on Pain Finds Significant Improvement

Radicle Science reports results demonstrated clinically meaningful improvements in pain across the different formulations of CBD and rare cannabinoids studied.

By using this website you agree to accept Medical Device News Magazine Privacy Policy